4N9G image
Entry Detail
PDB ID:
4N9G
Keywords:
Title:
Crystal Structure of a Computationally Designed RSV-Presenting Epitope Scaffold And Its Elicited Antibody 17HD9
Biological Source:
Host Organism:
PDB Version:
Deposition Date:
2013-10-21
Release Date:
2014-02-12
Method Details:
Experimental Method:
Resolution:
2.50 Å
R-Value Free:
0.29
R-Value Work:
0.26
R-Value Observed:
0.26
Space Group:
P 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Antibody 17HD9, Heavy Chain
Chain IDs:A, E, G (auth: H), I (auth: M)
Chain Length:230
Number of Molecules:4
Biological Source:Macaca mulatta
Polymer Type:polypeptide(L)
Description:Antibody 17HD9, Light Chain
Chain IDs:B, F, H (auth: L), J (auth: N)
Chain Length:215
Number of Molecules:4
Biological Source:Macaca mulatta
Polymer Type:polypeptide(L)
Description:Epitope Scaffold rsv_1isea_FFL_001_C
Chain IDs:C, D, K (auth: Y), L (auth: Z)
Chain Length:123
Number of Molecules:4
Biological Source:synthetic construct
Primary Citation

Abstact

Vaccines prevent infectious disease largely by inducing protective neutralizing antibodies against vulnerable epitopes. Several major pathogens have resisted traditional vaccine development, although vulnerable epitopes targeted by neutralizing antibodies have been identified for several such cases. Hence, new vaccine design methods to induce epitope-specific neutralizing antibodies are needed. Here we show, with a neutralization epitope from respiratory syncytial virus, that computational protein design can generate small, thermally and conformationally stable protein scaffolds that accurately mimic the viral epitope structure and induce potent neutralizing antibodies. These scaffolds represent promising leads for the research and development of a human respiratory syncytial virus vaccine needed to protect infants, young children and the elderly. More generally, the results provide proof of principle for epitope-focused and scaffold-based vaccine design, and encourage the evaluation and further development of these strategies for a variety of other vaccine targets, including antigenically highly variable pathogens such as human immunodeficiency virus and influenza.

Legend

Protein

Chemical

Disease

Primary Citation of related structures